Stay updated with breaking news from Gary Waanders. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
AC Immune to Present at the Jefferies Global Healthcare Conference in June 2024 Lausanne, Switzerland, May 28, 2023 - AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering
AC Immune Announces Upcoming Presentations at AD/PD™ 2024 Multiple presentations at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™ 2024)Andrea Pfeifer, Ph.D., CEO to lead AC Immune-sponsored symposium on alpha-synuclein pathologies Lausanne, Switzerland, February 22, 2024 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced upcoming presentations highlighting its preci
AC Immune’s Targeted Anti-pTau Active Immunotherapy for Alzheimer’s Disease Advances into Phase 2b Trial Potentially registration-enabling Phase 2b study (ReTain) will evaluate the effect of ACI-35.030 on cognition and Tau pathology in approximately 500 participants with preclinical Alzheimer’s disease (AD)Anti-pTau active immunotherapy being designed to potentially prevent or reduce cognitive decline could address need of over 315 million people globally1 with preclinical ADAC Immune to receive
AC Immune Announces Pricing of Underwritten Offering of Common Shares Lausanne, Switzerland, December 15, 2023 – AC Immune SA (Nasdaq: ACIU) (the...
AC Immune’s Targeted Anti-pTau Active Immunotherapy for Alzheimer’s Disease Advances into Phase 2b Trial Potentially registration-enabling Phase 2b study will evaluate the effect of ACI-35.030...